In second- or later-line setting, combination cut risk of disease progression or death by ...

Barclays 28th Annual Global Healthcare Conference March 11, 2026 11:30 AM EDTCompany ParticipantsBassil Dahiyat - Co-Founder, ...

Combination demonstrates deep PSA responses and favorable safety profile with plans to advance into Phase 3Data highlight the potential of this ...

Astellas Pharma Inc. and Vir Biotechnology, Inc. have entered into a global strategic collaboration to advance VIR-5500, an ...

Epcoritamab plus R-DHAX/C achieved 79% ORR and 69% CR, with median 1.4 months to response and early activity evident by the first week-6 assessment. Over half of patients reached ASCT after ...

Among the most promising tools of cancer therapy, engineered immune cells known as chimeric antigen-receptor (CAR) T cells have already transformed the treatment of blood cancers. Yet, despite their ...

A “significant number of patients” could see a cure for multiple myeloma within the next two decades, one expert told ...

Barclays 28th Annual Global Healthcare Conference March 11, 2026 1:30 PM EDTCompany ParticipantsAnthony Pagano - Executive VP ...

The remote control doesn’t trigger the self-destruction of the CAR T cells, but simply prompts them to disengage from their cancerous targets.

BioAtla has engaged Tungsten Advisors as the Company’s exclusive strategic financial advisor. There can be no assurance that this process will result in any such transaction. BioAtla does not intend ...

Immunocore reports fourth quarter and full year 2025 financial results and provides a business update KIMMTRAK (tebentafusp-tebn) Q4 net sales ...

As of Thursday, February 26, Ligand Pharmaceuticals Incorporated’s LGND share price has dipped by 5.99%, which has investors questioning if this is right time to buy.